FDA advisors recently voted in favor of making NARCAN (naloxone) available OTC ✨ Here's a quick refresher on counseling points for the adminstration of NARCAN nasal spray 🧵 #TwitteRx #MedTwitter #PharmEd #MedEd buff.ly/3I9guRs

🔥Current developments in gastric cancer: from molecular profiling to treatment strategy Nature Reviews Gastroenterology & Hepatology doi.org/10.1038/s41575… 👏Extensive review & summary of key trials 😅Claudia 18.2 can be added, FGFR2 hopefully soon -> on the way to #PrecisionOncology ESMO - Eur. Oncology OncoAlert

Updated metastatic #lungcancer #algorithm where Rx is w/palliative intent! Adagrasib was not approved at the time of our 🗣 with @esinghimd Given PFS alone, do you offer KRASi to all G12c patients? When do you use dual IO? x.com/oncbrothers/st… #lcsm #OncTwitter #MedTwitter

CM816 trial 👑: Neoadjuvant chemo + IO improved 3-year EFS vs neoadj Ch alone with lowe 🧠 recurrences with chemoIO approach💡Challenges: Do we need ADJ IO after the neoadj CT+IO approach?Role of this strategy in stage I/II NSCLC? In stage III: CM816 vs PACIFIC? ESMO - Eur. Oncology #ELCC2023

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes mdpi.com/2168336 #mdpiijms via IJMS MDPI #MDS

I’m incredibly proud to share that we have completed the submission of our BLAs for the potential first-ever CRISPR-based therapy! Hope this milestone will be the first of many. Congrats to the team CRISPR Therapeutics Vertex Pharmaceuticals and thanks to our investigators and patients on the trial

Somatic mutations accumulate in “normal” non-cancerous tissues (blood, skin, liver). But why are mutant clones selected? Do they merely proliferate more, selfishly? Or can clones adapt to disease? Could they protect tissues? We shed light on this: authors.elsevier.com/a/1gua9L7PXmc1- 1/10

Immediate hypersensitivity reactions to antineoplastic agents: A practical guide for the oncologist 💥A great clinical guide 📌The most important message for us oncologists: When you suspect anaphylaxis, immediately administer 0.5 mg epinephrine IM❗️ OncoAlert

Neoadjuvant chemo-endocrine combination in HR+/HER2- BC: Is it a combination we should avoid or can it be effective in the right patient? 🔎We attempted to investigate this difficult question with a pooled analysis of a limited number of RCTs: Five RCTs, 630 patients

🔥EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma🔥 Journal of Hepatology doi.org/10.1016/j.jhep… 👏Very detailed recommendations on diagnostic, prognostic, and therapeutic management of iCCA ESMO - Eur. Oncology EASL Education ENS-CCA #livertwitter OncoAlert

Such an important slide to guide transplant decisions in AML IACH Mohamad Mohty Mohamad Mohty Dr Charles Craddock speaking right now on optimising outcomes for AML post Allograft

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Ultraviolet light shapes the evolution of precancerous cells go.nature.com/42Cvcc8

Perspective in Science Magazine on how T cells primed in the gut influence immune responses to extra intestinal cancers. science.org/doi/10.1126/sc… Original papers science.org/doi/10.1126/sc… science.org/doi/10.1126/sc… Two complementary observations converging on the same integrin.

How I treat AML incorporating the updated classifications and guidelines ashpublications.org/blood/article/… #AML #leusm

😂😂

Accurate Stoichiometry Prediction of Protein Complexes by Integrating AlphaFold3 and Template Information 1. This study presents a new method, PreStoi, which combines AlphaFold3 with template-based information to predict the stoichiometry (subunit counts) of protein complexes, a

Targeting protein–ligand neosurfaces with a generalizable deep learning tool nature 1. This study introduces MaSIF-neosurf, a novel deep learning framework for designing proteins that target neosurfaces—protein-ligand interfaces—using geometric deep learning and molecular

Cancer statistics in 2025 🇺🇸- new report 🚨 Cancer is becoming a new disease. We're seeing a fundamental shift in who gets cancer, moving from a predominantly male, elderly disease to one that increasingly affects women and younger people. Key highlights 🧵

Happy to share our latest publication in Journal of Medicinal Chemistry, highlighting the discovery of precision chemotype for t(8;21) AML. Read the full article here..pubs.acs.org/doi/10.1021/ac…